114 related articles for article (PubMed ID: 17497466)
1. Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy.
Horita Y; Tadokoro M; Taura K; Ashida R; Hiu M; Taguchi T; Furusu A; Kohno S
Ren Fail; 2007; 29(4):441-6. PubMed ID: 17497466
[TBL] [Abstract][Full Text] [Related]
2. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
Trimarchi H; Muryan A; Young P; Forrester M; Iotti A; Pereyra H; Lombi F; Seminario O; Alonso M; Iotti R
Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
[TBL] [Abstract][Full Text] [Related]
3. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
Horita Y; Taura K; Taguchi T; Furusu A; Kohno S
Nephrology (Carlton); 2006 Oct; 11(5):462-6. PubMed ID: 17014562
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy using prednisolone and cyclophosphamide slows the progression of moderately advanced IgA nephropathy.
Tsuruya K; Harada A; Hirakata H; Mitsuiki K; Johko T; Kondoh H; Takechi S; Fujishima M
Clin Nephrol; 2000 Jan; 53(1):1-9. PubMed ID: 10661476
[TBL] [Abstract][Full Text] [Related]
5. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment.
McIntyre CW; Fluck RJ; Lambie SH
Clin Nephrol; 2001 Sep; 56(3):193-8. PubMed ID: 11597033
[TBL] [Abstract][Full Text] [Related]
6. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy.
Horita Y; Tadokoro M; Taura K; Suyama N; Taguchi T; Miyazaki M; Kohno S
Hypertens Res; 2004 Dec; 27(12):963-70. PubMed ID: 15894837
[TBL] [Abstract][Full Text] [Related]
7. Histologically advanced IgA nephropathy treated successfully with prednisolone and cyclophosphamide.
Mitsuiki K; Harada A; Okura T; Higaki J
Clin Exp Nephrol; 2007 Dec; 11(4):297-303. PubMed ID: 18085391
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of clinical and histological features in IgA nephropathy treated with steroid and angiotensin receptor blockers.
Choi S; Lee D; Jeong KH; Moon JY; Lee SH; Lee TW; Ihm CG
Clin Nephrol; 2009 Nov; 72(5):353-9. PubMed ID: 19863877
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy.
Manno C; Gesualdo L; D'Altri C; Rossini M; Grandaliano G; Schena FP
J Nephrol; 2001; 14(4):248-52. PubMed ID: 11506246
[TBL] [Abstract][Full Text] [Related]
10. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
Li PK; Leung CB; Chow KM; Cheng YL; Fung SK; Mak SK; Tang AW; Wong TY; Yung CY; Yung JC; Yu AW; Szeto CC;
Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
[TBL] [Abstract][Full Text] [Related]
11. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.
Russo D; Minutolo R; Pisani A; Esposito R; Signoriello G; Andreucci M; Balletta MM
Am J Kidney Dis; 2001 Jul; 38(1):18-25. PubMed ID: 11431176
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function.
Moriyama T; Honda K; Nitta K; Yumura W; Nihei H
Clin Exp Nephrol; 2004 Sep; 8(3):237-42. PubMed ID: 15480901
[TBL] [Abstract][Full Text] [Related]
13. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
Manno C; Torres DD; Rossini M; Pesce F; Schena FP
Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran.
Soleymanian T; Najafi I; Salimi BH; Broomand B
Ren Fail; 2011; 33(6):572-7. PubMed ID: 21663387
[TBL] [Abstract][Full Text] [Related]
16. Antiproteinuric effect of losartan in non-diabetic renal disease is not dependent on ACE insertion/deletion polymorphism.
Park HC; Choi HY; Kim BS; Kang SW; Choi KH; Ha SK; Lee HY; Han DS
Kidney Blood Press Res; 2006; 29(4):216-24. PubMed ID: 16960460
[TBL] [Abstract][Full Text] [Related]
17. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis.
Renke M; Tylicki L; Rutkowski P; Rutkowski B
Scand J Urol Nephrol; 2004; 38(5):427-33. PubMed ID: 15764256
[TBL] [Abstract][Full Text] [Related]
18. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B
Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
[TBL] [Abstract][Full Text] [Related]
19. Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy.
Shimizu A; Takei T; Uchida K; Tsuchiya K; Nitta K
Hypertens Res; 2008 Sep; 31(9):1711-7. PubMed ID: 18971549
[TBL] [Abstract][Full Text] [Related]
20. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up.
Kanno Y; Okada H; Saruta T; Suzuki H
Clin Nephrol; 2000 Nov; 54(5):360-5. PubMed ID: 11105796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
